Lamitrin

Amiodarone (Opacorden, Polpharma, Starogard Gdański, Poland), lamotrigine (Lamitrin, GlaxoSmithKline, Brentford, Middlesex, UK), oxcarbazepine (Trileptal, Novartis, Nürnberg, Germany), topiramate (Topamax, Janssen-Cilag International NV, Beerse, Belgium), pregabalin (Lyrica, Pfizer Limited, Sandwich, Kent, UK) were suspended in a 1% aqueous solution of Tween 80 (Sigma-Aldrich, St. Louis, MO, USA). All drugs or vehicle (in control groups) were administered intraperitoneally (i.p.) in a volume of 10 mL/kg body weight. Amiodarone and oxcarbazepine were applied 30 min., lamotrigine and topiramate 60 min., pregabalin 120 min. before tests, respectively. Doses of antiepileptic drugs and amiodarone, as well as their application time, were based on our experimental experiences published elsewhere [2 (link),16 (link)].

In the study, the following drugs were used: antiarrhythmic drug—mexiletine (Sigma-Aldrich, Slovakia), antiepileptic drugs: lamotrigine (Lamitrin, GlaxoSmithKline, Great Britain), oxcarbazepine (Trileptal, Novartis Pharma, Germany), pregabalin (Lyrica, Pfizer, Great Britain), topiramate (Topamax, Janssen-Cilag, Belgium). mexiletine was dissolved in distilled water whereas antiepileptic drugs were suspended in 1% solution of Tween 80 (Sigma, St. Louis, MO, USA). Drug solutions were prepared freshly on each day of tests. All examined drugs were administered intraperitoneally in a volume of 10 ml/kg of body weight: mexiletine—15 min, oxcarbazepine—30 min, lamotrigine—60 min, topiramate—60 min, while pregabalin—120 min before the tests.